

IPAR



**Publicly Available Assessment Report for a
Veterinary Medicinal Product**

Combifluke Oral Suspension for Sheep

PRODUCT SUMMARY

Name, strength and pharmaceutical form	Combifluke Oral Suspension for Sheep
Active substances	Oxfendazole and closantel
Marketing Authorisation Holder	Norbrook Laboratories (Ireland) Limited Rossmore Industrial Estate Monaghan Ireland
Legal basis of application	Informed consent application in accordance with Article 13c of Directive 2001/82/EC as amended.
Target species	Sheep
Indication for use	For the treatment of mixed infections of mature and developing immature gastrointestinal roundworms, lungworms, tapeworms and fluke or sheep nasal fly in sheep and lambs. It is ovicidal against nematode eggs and delays egg laying in trematodes (fluke).
ATCvet code	QP52AC52

PUBLIC ASSESSMENT REPORT

The public assessment report reflects the scientific conclusion reached by the HPRA at the end of the evaluation process and provides a summary of the grounds for approval of the marketing authorisation for the specific veterinary medicinal product. It is made available by the HPRA for information to the public, after the deletion of commercially confidential information. The legal basis for its creation and availability is contained in Article 25.4 of EC Directive 2001/82/EC as amended by Directive 2004/28/EC for veterinary medicinal products. It is a concise document which highlights the main parts of the documentation submitted by the applicant and the scientific evaluation carried out by HPRA leading to the approval of the product for marketing in Ireland.

The Summary of Product Characteristics (SPC) for this product is available on the HPRA website.

I. SCIENTIFIC OVERVIEW

The quality, safety and efficacy aspects of this product are identical to Parafend Plus (Norbrook Laboratories, VPA 10999/099/001). The initial application for Parafend Plus was assessed before there was a requirement to have a public assessment report, therefore no details in this section are available. Please refer to section VI for significant post-approval changes which are important for the quality, safety and efficacy of the product.

II. QUALITY ASPECTS

See section I.

III SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

See section I.

IV. CLINICAL ASSESSMENT

See section I.

V. OVERALL CONCLUSION AND BENEFIT/RISK ASSESSMENT

On the basis of the original data submitted, the HPRA considered that Combifluka demonstrated adequate evidence of efficacy for the approved indications as well as a satisfactory benefit/risk profile and therefore granted a marketing authorisation.

VI. POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the HPRA website.